Columvi
Roche’s Columvi (glofitamab) for patients with R/R diffuse large B-cell lymphoma has received approval from the European Commission
SG Tylor
Source – Roche On 11 July 2023 Roche announced that the European Commission (EC) has given conditional approval for Columvi ...
Roche’s Columvi and AbbVie’s Epkinly: The Battle for Breakthroughs in Large b Cell Lymphoma Treatment
SG Tylor
Roche’s Columvi (glofitamab) receives FDA accelerated approval for treatment of Large b Cell Lymphoma, sparking a rivalry with AbbVie and ...
Glofitamab-gxbm receives FDA approval for relapsing or resistant DLBCL
SG Tylor
Source – Roche Columvi (Glofitamab-gxbm) has been given expedited clearance by the FDA for the treatment of adult patients with ...
